BioCentury | Oct 7, 2013
Clinical News

Vaxem-Hib regulatory update

...Takeda submitted an NDA to Japan's Ministry of Health, Labor and Welfare for TAK-816 to prevent...
...develop and commercialize TAK-816 from Novartis under a 2009 deal. Novartis markets the product as Vaxem-Hib...
...Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Vaxem-Hib ( TAK-816...
BioCentury | Jan 16, 2012
Company News

Takeda, Osaka University deal

...to develop its pediatric vaccine products, including Haemophilus influenzae type B ( Hib ) vaccine TAK-816...
BioCentury | Dec 12, 2011
Company News

Takeda infectious news

...to develop Takeda's pediatric vaccine products, including Haemophilus influenzae type B ( Hib ) vaccine TAK-816...
...II trial of TAK-361S in Japan. Takeda has exclusive, Japanese rights to develop and commercialize TAK-816...
...Basel, Switzerland) under a 2009 deal. In June, Takeda began a Phase III trial of TAK-816...
BioCentury | Jun 1, 2009
Company News

Novartis, Takeda sales and marketing update

...Takeda received exclusive rights in Japan to develop and commercialize Novartis' Vaxem-Hib to prevent Haemophilus influenzae...
Items per page:
1 - 4 of 4